CN101773669A - 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 - Google Patents

用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 Download PDF

Info

Publication number
CN101773669A
CN101773669A CN200910252323A CN200910252323A CN101773669A CN 101773669 A CN101773669 A CN 101773669A CN 200910252323 A CN200910252323 A CN 200910252323A CN 200910252323 A CN200910252323 A CN 200910252323A CN 101773669 A CN101773669 A CN 101773669A
Authority
CN
China
Prior art keywords
hmgb1
cell
hmg box
hmg
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910252323A
Other languages
English (en)
Chinese (zh)
Inventor
马尔科·E·比安基
蒂齐亚纳·博纳尔迪
保拉·斯卡菲迪
苏珊·米勒
伯纳德·德格里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio3 Res S R L
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Publication of CN101773669A publication Critical patent/CN101773669A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200910252323A 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 Pending CN101773669A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ITMI2001A000562 2001-03-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN028065670A Division CN1537014B (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Publications (1)

Publication Number Publication Date
CN101773669A true CN101773669A (zh) 2010-07-14

Family

ID=11447291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200910252323A Pending CN101773669A (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
CN028065670A Expired - Fee Related CN1537014B (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN028065670A Expired - Fee Related CN1537014B (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Country Status (14)

Country Link
US (4) US7754217B2 (https=)
EP (1) EP1368060B1 (https=)
JP (1) JP4822654B2 (https=)
CN (2) CN101773669A (https=)
AT (1) ATE468137T1 (https=)
AU (1) AU2002247977C1 (https=)
CA (1) CA2439530C (https=)
DE (1) DE60236413D1 (https=)
DK (1) DK1368060T3 (https=)
ES (1) ES2346408T3 (https=)
IT (1) ITMI20010562A1 (https=)
MX (1) MXPA03008364A (https=)
PT (1) PT1368060E (https=)
WO (1) WO2002074337A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
AU2003228099A1 (en) 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
PL1768677T3 (pl) * 2004-07-02 2009-01-30 Creabilis Therapeutics Spa Kwasy nukleinowe do leczenia patologii związanych z HMGB-1
EP1768693A1 (en) 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Use of hmgb1 for wound healing
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
NZ553809A (en) * 2004-09-03 2010-03-26 Creabilis Therapeutics Spa Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1
US7585504B2 (en) 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EP1919979B2 (en) 2005-08-25 2017-03-29 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
AU2007296843C1 (en) 2006-09-15 2012-08-16 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
ES2654542T3 (es) 2008-04-30 2018-02-14 Genomix Co., Ltd. Procedimiento de recolección de células funcionales in vivo con alta eficiencia
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
US9278108B2 (en) 2009-07-16 2016-03-08 Nec Solution Innovators, Ltd. HMGB1 binding nucleic acid molecule and applications thereof
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US11191786B2 (en) 2009-10-28 2021-12-07 StemRIM Inc. Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood
AU2011322482B2 (en) 2010-10-30 2017-03-23 Oxford University Innovation Limited Treatment for Dupuytren's disease
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
US9550825B2 (en) 2013-01-28 2017-01-24 Evec Inc. Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
AU2016366515A1 (en) 2015-12-11 2018-06-21 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
US11969459B2 (en) 2017-01-27 2024-04-30 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
JP7455433B2 (ja) * 2020-04-22 2024-03-26 チュラーロンコーン ユニバーシティー Ｄｎａを回復する及びｄｎａ損傷を防止する組成物及び方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
AU1832797A (en) 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
AU2696097A (en) 1996-04-16 1997-11-07 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
EP1768693A1 (en) * 2004-07-20 2007-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'Immacolata Concezione - Istituto Dermopatico Dell'Immacolata Use of hmgb1 for wound healing
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN1537014A (zh) 2004-10-13
AU2002247977B8 (en) 2007-03-15
EP1368060B1 (en) 2010-05-19
HK1069316A1 (en) 2005-05-20
US8058239B2 (en) 2011-11-15
US20100172896A1 (en) 2010-07-08
AU2002247977C1 (en) 2008-09-18
WO2002074337A1 (en) 2002-09-26
AU2002247977A1 (en) 2002-10-03
WO2002074337A8 (en) 2003-08-28
DE60236413D1 (de) 2010-07-01
US20080171052A1 (en) 2008-07-17
CA2439530C (en) 2016-11-08
JP2004523579A (ja) 2004-08-05
US7754217B2 (en) 2010-07-13
CN1537014B (zh) 2012-04-25
ATE468137T1 (de) 2010-06-15
ES2346408T3 (es) 2010-10-15
MXPA03008364A (es) 2004-11-12
JP4822654B2 (ja) 2011-11-24
US20040136979A1 (en) 2004-07-15
EP1368060A1 (en) 2003-12-10
CA2439530A1 (en) 2002-09-26
AU2002247977A2 (en) 2004-02-26
DK1368060T3 (da) 2010-08-30
PT1368060E (pt) 2010-08-24
AU2002247977B2 (en) 2006-12-14
ITMI20010562A1 (it) 2002-09-16
US20100297107A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CN101773669A (zh) 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
Segerer et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis
JP6168532B2 (ja) 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
DE3888224T2 (de) Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
JP4252111B2 (ja) Ａｌ−１神経栄養因子、ｅｐｈ関連チロシンキナーゼレセプターのためのリガンド
Kim et al. The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis
JPH01135724A (ja) 非特異的炎症の治療法
JP2930713B2 (ja) タンパク質ホルモン形成の抑制用の組成物およびその使用法
JPH029391A (ja) 大食細胞誘導炎症性神経細胞
Kagami et al. β1-integrins and glomerular injury
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
JPH05276986A (ja) 単球遊走性サイトカインに対する抗体
WO2003022992A2 (en) Mammalian genes; related reagents
JPH0644877B2 (ja) 抗ヒト・フイブロネクチンモノクロ−ナル抗体
DE69835170T2 (de) Polypeptid und dafür kodierendes Nukleinsäure
HK1146703A (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1069316B (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
JPH08208515A (ja) リウマチ治療剤
LeMosy Biochemical analysis of a human glioma laminin: evidence for a novel glial A chain
WO2000041537A2 (en) Use of desert hedgehog protein
JPH111496A (ja) クサリヘビ科ヘビの毒腺由来のアポトーシス誘導性タンパク質、およびその利用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Free format text: FORMER OWNER: BIANCHI MARCO E.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20110125

Address after: Milan Italy

Applicant after: BIO3 Res S. R. L

Address before: Milan Italy

Applicant before: BIO3 Res S. R. L

Co-applicant before: Bianchi Marco E.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1146703

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20161116

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1146703

Country of ref document: HK